Mucosal leishmaniasis in travelers with leishmania braziliensis complex returning to israel

Michal Solomon, Nadav Sahar, Felix Pavlotzky, Aviv Barzilai, Charles L. Jaffe, Abedelmajeed Nasereddin, Eli Schwartz

Research output: Contribution to journalArticlepeer-review

Abstract

Mucosal leishmaniasis (ML) is a complication of New World cutaneous leishmaniasis (CL) caused mainly by Leishmania (Viannia) braziliensis. This retrospective study investigated all cases of ML caused by L. (V.) braziliensis in a tertiary medical center in Israel, evaluating the risk factors, clinical presentations, diagnosis, treatment, and outcome of mucosal involvement in ML caused by L. (V.) braziliensis in travelers returning to Israel. During 1993–2015, a total of 145 New World CL cases were seen in travelers returning from Bolivia; among them, 17 (11.7%) developed ML. Nasopharyngeal symptoms developed 0–3 years (median 8 months) after exposure. The only significant risk factor for developing ML was the absence of previous systemic treatment. Among untreated patients, 41% developed ML, compared with only 3% of treated patients (p = 0.005). Systemic treatment for CL seems to be a protective factor against developing ML.

Original languageEnglish
Pages (from-to)642-648
Number of pages7
JournalEmerging Infectious Diseases
Volume25
Issue number4
DOIs
StatePublished - Apr 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Mucosal leishmaniasis in travelers with leishmania braziliensis complex returning to israel'. Together they form a unique fingerprint.

Cite this